
AbbVie’s Rinvoq receives EC approval to treat adults with giant cell arteritis
AbbVie’s Rinvoq (upadacitinib) has been granted marketing authorisation by the European Commission (EC) to treat giant cell arteritis (GCA), making it the first oral Janus kinase (JAK) inhibitor to be approved in the EU for adults with the autoimmune …